News Highlights


2011 FDA authorized JN's IND for conducting Conjugated Meningococcal vaccine human trials in Hanford, California



2011 Neurology scientists bags Stroke Grant Award - US Govt.



2006-2011 Meningitis vaccine for Disease outbreaks in India & sub-Saharan





Dr.Reddy at Pharma conf-Amsterdam



Dr. Orten & Dr. Reddy - at CNS World Summit



  Promising New Study Attempts to Perfect a Genital Herpes Vaccine   

   Meningitis serogroup 'B' challenge it presents concerning vaccine development  at JN


Welcome to JN-International Medical Corporation [JN], a U.S. based private  biopharmaceutical corporation, has been developing vaccines for infectious disease and neurological disorders. Emphasis on our 20-years of basic research combined with an applied focus on specific medical needs was instrumental to success and growth of this corporation. The style of JN, our new corporate website, reflects our values and gives information on our principle business areas. So happy reading!


Scientific Discovery since 1998 

 JN's Exports most since 1999


JN exports vaccines & diagnostics to over 24 countries since 1999 and are contract manufactured in USA, India, Brazil and Eastern Europe, The export products are the World Health Organization (WHO) pre-qualified and registered at the Ministry of Health. JN subsidiaries and distributors import the products directly from the manufacturers. JN is equipped with cold room facilities in sub-Saharan Africa and South East Asia to handle cold chain requirements of WHO.






The corporation 

JNI Medical Corp - Admin Building

Do you Know? JN is the 3rd BioPharma, developed patented Meningococcal meningitis serogroups A/C/Y/W135 diphtheria toxoid conjugate vaccine (NmVac-4dt) which is now human phase in USA and the vaccine is proven safety and efficacy in sub-Saharan Africa for all ages JN also developing vaccine for Genital Herpes and therapeutic Ischemic Stroke. Inc5000 Fastest Growing Company



Meningitis outbreaks  

Meningococcal meningitis Disease


 Serogroup shift may threatens epidemic and pandemic outbreaks of meningitis JN developing 13 serogroups including Meningitis B combo conjugate vaccine.


Vaccine: NmVac4-ACYW135 DTNmVac-4dt is among the most complex biotech or biologic products. It’s a combination vaccine that contains four 4 different vaccines in one and can be used with any combination by the geographic prevalence of the disease causing serogroup A, C, Y & W-135


Neurological THERAPIES
Proof of concept of stroke and neurological diseases


Research JN neurology team has developed Biomarkers and Therapeutics to intervene TIA / Stroke, Epilepsy, Alzheimer's.

  1. Vaccine saves mice

  2. Auto Antibodies NEWS

  3. Biomarkers

  4. Stroke therapeutic



Filled Commitment



JN & Clinton Global


US President Malaria Initiative & JN International Medical Corporation


© 1998-2012 JN-International, Inc. Oakland, Nebraska 68045, USA . BYLAWS TERMS OF USE LEGAL DISCLAIMER